Yahoo
NasdaqGS - Delayed Quote USD

Madrigal Pharmaceuticals, Inc. (MDGL)

541.08 -1.53 (-0.28%)
At close: September 4 at 4:00:01 PM EDT
541.08 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade MDGL on Coinbase
Chart Range Bar
Loading chart for MDGL
  • Previous Close 542.61
  • Open 536.82
  • Bid 511.93 x 100
  • Ask 512.55 x 100
  • Day's Range 536.43 - 547.92
  • 52 Week Range 393.61 - 615.00
  • Volume 177,162
  • Avg. Volume 352,424
  • Market Cap (intraday) 12.501B
  • Beta (5Y Monthly) -0.99
  • PE Ratio (TTM) --
  • EPS (TTM) -14.00
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 678.06

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

www.madrigalpharma.com

915

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDGL
7.09%
S&P 500 (^GSPC)
12.75%

1-Year Return

MDGL
25.48%
S&P 500 (^GSPC)
18.71%

3-Year Return

MDGL
192.25%
S&P 500 (^GSPC)
70.93%

5-Year Return

MDGL
569.99%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 364.25M
Earnings -57.94M
Profit Margin -15.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
0
100M
200M
300M
-35.0%
-30.0%
-25.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

543.00
678.06 Average
541.08 Current
962.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/4/2026
Analyst Wolfe Research
Rating Action Upgrade
Rating Outperform
Price Action Announces
Price Target 605

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -25.32%

  • Return on Assets (ttm)

    -17.84%

  • Return on Equity (ttm)

    -53.31%

  • Revenue (ttm)

    1.28B

  • Net Income Avi to Common (ttm)

    -325.1M

  • Diluted EPS (ttm)

    -14.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    838.75M

  • Total Debt/Equity (mrq)

    66.40%

  • Levered Free Cash Flow (ttm)

    -80.47M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: